| MacDonald, Thomas M |
| Completed | N/A | 200 | Europe | HPLC-MS/MS-guided intervention, Standard care | University of Manchester, British Heart Foundation, Manchester Academic Health Science Centre, Omron Healthcare Co., Ltd. | Hypertension, Adherence, Medication | 08/23 | 09/23 | | |
| Lang, Chim |
| Recruiting | 1/2 | 80 | Europe | AC01 | AnaCardio AB | Heart Failure With Reduced Ejection Fraction | 06/25 | 06/25 | | |
| Recruiting | N/A | 1600 | Europe | | Institut National de la Santé Et de la Recherche Médicale, France | Cardiomyopathy, Diabetic | 10/27 | 10/27 | | |
| George, Jacob |
| Active, not recruiting | 3 | 871 | Europe, Canada, Japan, US, RoW | Bepirovirsen, Placebo | GlaxoSmithKline, GlaxoSmithKline Research & Development Limited | Chronic Hepatitis B, Hepatitis B, Chronic | 11/25 | 05/26 | | |
B-UNITED, NCT06537414: A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB) |
|
|
| Recruiting | 2 | 280 | Europe, Canada, Japan, US, RoW | Daplusiran/Tomligisiran Dose Level 1, Daplusiran/Tomligisiran Dose Level 2, Bepirovirsen, Placebo | GlaxoSmithKline | Chronic Hepatitis B Virus Infection, Hepatitis B | 10/27 | 10/27 | | |
| Recruiting | N/A | 300 | RoW | GeneXpert HBV DNA Viral Load Assay, Dried Blood Spot HBV DNA test | Kirby Institute | Hepatitis B | 12/24 | 12/25 | | |
NCT05042544: The National Australian HCV Point-of-Care Testing Program |
|
|
| Recruiting | N/A | 40000 | RoW | Point-of-Care Testing | Kirby Institute, Flinders University | Hepatitis C | 12/24 | 12/26 | | |
| Recruiting | N/A | 10000 | RoW | No intervention | Kirby Institute | Hepatitis B | 07/26 | 07/27 | | |
NCT04455932: HCC Surveillance: Comparison of Abbreviated Non-contrast MRI and Ultrasound Surveillance in Cirrhotic Patients With Suboptimal Ultrasound Visualisation |
|
|
| Recruiting | N/A | 476 | RoW | Abbreviated non-contrast MRI of the liver, aNC-MRI, Ultrasound surveillance, US surveillance, Multiphase contrast-enhanced liver MRI, Multiphase liver MRI | Concord Repatriation General Hospital | Hepatocellular Carcinoma, HCC | 12/26 | 03/27 | | |
| Dillon, John |
| Recruiting | 3 | 50 | US | Dialysis | Fresenius Medical Care North America | Acute Kidney Injury, ESRD | 11/24 | 03/25 | | |
REACT, NCT05441852: A Study to Detect Hyperkalemia Using Smartphone-enabled Electrocardiogram (EKG) |
|
|
| Completed | N/A | 1151 | US | | Mayo Clinic | Hyperkalemia | 07/23 | 07/23 | | |
| Innes, Nicola |
NCT06012409: Evaluation of the Occlusal Effects of the Hall Technique and Investigation of Children's Satisfaction |
|
|
| Completed | N/A | 39 | RoW | Hall Technique Prefabricated Metal Crown | Aydin Adnan Menderes University, Cardiff University | Dental Caries in Children | 09/23 | 01/24 | | |
| Chalmers, James D |
BATMAN, NCT05582798: Bronchiectasis Alpha-1 Augmentation Trial- Modulating Airway Neutrophil Function |
|
|
| Completed | 4 | 20 | Europe | Alpha 1-Proteinase Inhibitor 180mg/kg, Prolastin-C Liquid, Alpha 1-Proteinase Inhibitor 120mg/kg, Sodium chloride | University of Dundee | Bronchiectasis Adult | 08/24 | 08/24 | | |
| Completed | 3 | 100 | Europe, Canada, US, RoW | Benralizumab, Placebo to Benralizumab | AstraZeneca | Non-cystic Fibrosis Bronchiectasis | 04/24 | 04/24 | | |
|
| Completed | 3 | 806 | Europe, Canada, US, RoW | Placebo, Mepolizumab | GlaxoSmithKline, PPD DEVELOPMENT, LP | Pulmonary Disease, Chronic Obstructive | 08/24 | 08/24 | | |
|
|
|
|
|
| Recruiting | 3 | 288 | Europe | Hypertonic saline, MucoClear 6%, HTS, Carbocysteine 750 MG, Mucodyne | Belfast Health and Social Care Trust, Queen's University, Belfast | Bronchiectasis | 09/24 | 09/24 | | |
| Recruiting | 2 | 77 | Europe | Aztreonam lysine, Cayston, Placebo, Lactose monohydrate | University of Dundee, Gilead Sciences | Bronchiectasis Adult | 09/25 | 09/25 | | |
NCT06166056: A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Inhaled CHF6333 After Single Doses in Healthy Volunteers and After Single and Repeated Doses in Subjects With Bronchiectasis |
|
|
| Recruiting | 1/2 | 45 | Europe | CHF6333, CHF6333 Placebo | Chiesi Farmaceutici S.p.A. | Bronchiectasis | 06/25 | 06/25 | | |
BRIDGE, NCT03791086: The Study - Bronchiectasis Research Involving Databases, Genomics and Endotyping |
|
|
| Recruiting | N/A | 1000 | Europe | | University of Dundee | Bronchiectasis Adult | 02/27 | 02/27 | | |
| Sammler, Esther |
LIGHTHOUSE, NCT05418673 / 2022-000747-77: A Study to Assess if BIIB122 Tablets Are Safe and Can Slow Worsening of Early-Stage Parkinson's Disease in Participants With Specific LRRK2 Genetic Variants Between the Ages of 30 and 80 Using the Movement Disorder Society-Unified Parkinson's Disease Rating Scale |
|
|
| Terminated | 3 | 7 | Europe, US | BIIB122, DNL151, BIIB122-Matching Placebo | Biogen, Denali Therapeutics Inc. | Parkinson Disease | 07/23 | 07/23 | | |
| Active, not recruiting | 3 | 600 | Europe | Rivastigmine Transdermal System, Placebo Transdermal System | University of Bristol, Royal United Hospitals Bath NHS Foundation Trust | Parkinson Disease | 05/24 | 02/25 | | |
LUMA, NCT05348785 / 2021-004849-20: A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80 |
|
|
| Recruiting | 2 | 640 | Europe, Canada, Japan, US, RoW | BIIB122, DNL151, BIIB122-Matching Placebo | Biogen, Denali Therapeutics Inc. | Parkinson Disease | 12/25 | 12/25 | | |
ACTIVATE, NCT05819359: Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD |
|
|
| Active, not recruiting | 2 | 237 | Europe, Canada, US | BIA 28-6156 10 mg, BIA 28-6156 60 mg, Placebo | Bial R&D Investments, S.A. | Parkinson's Disease | 03/26 | 07/26 | | |
| Active, not recruiting | N/A | 25000 | Europe, Canada, US, RoW | | CENTOGENE GmbH Rostock | Parkinson´s Disease | 12/25 | 12/25 | | |
